Cordis' new stent approved for use in Europe
The USA's Cordis Corp, a world-leader in the drug-eluting stent market, says that its Cypher Select Plus has become the first third-generation drug-eluting stent to receive the European Community mark of approval.
The company, which is owned by US health care major Johnson & Johnson, says it will introduce the product in Europe in September, with a full market launch by the end of the year.
According to Cordis, its enhanced stent delivery system, offers exceptional deliverability, noting that, in addition to its flexible stent design and short tip, it features hydrophilic coating technology that is "significantly more lubricious" than previous Cypher Stent products, thus "greatly increasing a physician's ability to successfully navigate challenging coronary arteries."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze